Home
Allucent

Allucent Market Share Analysis for May 2026

Allucent is a global, full-service CRO specializing in biotech & small-to-mid-size pharma. Get expert clinical research solutions & accelerate your development.

Health > Biotechnology and Pharmaceuticals

Domainallucent.com

Year Founded1988

Employees1001 - 5000

Annual Revenue$75M - $100M

Allucent

Allucent (including company regionals)

allucent.com

See more website traffic and engagement information

Allucent Revenue up to May 2026 is 75M - 100M

revenue generated by Allucent top domains

Allucent top domains revenue over 3 years

Revenue for Allucent top domains

allucent.com75M - 100M

See more with Sales Intelligence

Total visits to Allucent's top domains

Understand Allucent market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

allucent.com90.3K

See more with Sales Intelligence

Avg. visit duration in Allucent's top domains

Analyze Allucent engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

allucent.com00:00:41

See more with Sales Intelligence

Avg. pageviews on Allucent's top domains

See how Allucent keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

allucent.com1.34

See more with Sales Intelligence

Allucent top competitors by domain

Top similar sites in May 2026, ranked by their affinity

certara.comCompany NameCertaraEmployees1001 - 5000HQUnited States, New Jersey, PrincetonAnnual revenue$200M - $500MTotal visits111.9KHealth > Pharmacy

Top technologies used by Allucent

These are the website technologies, by industry, used by Allucent top domains

Advertising (9)

Google Adsense

Payment & Currencies (8)

Cart Functionality

Content Management System (5)

WordPress

Widget (5)

Twemoji

More Technologies

15

See all

News & Signals from Allucent

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsQuantum BioPharma Ltd. partnered with Allucent on Mar 30th '26.TORONTO, March 30, 2026 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that it has entered into a binding Letter of Intent (LOI) with Allucent, a global contract research organization with extensive experience supporting central nervous system clinical trials, to support the planned Phase 2 clinical trial of Lucid-MS for the treatment of multiple sclerosis (MS).

NewsSilo Pharma Inc. partnered with Allucent on Dec 30th '25.SARASOTA, FL, Dec. 30, 2025 (GLOBE NEWSWIRE) - Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a diversified developmental stage biopharmaceutical and cryptocurrency treasury company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced it has entered into a non-binding Letter of Intent ("LOI") with Allucent (US) LLC ("Allucent"), a global clinical research organization (CRO), to provide clinical research services for two planned Phase 1 studies evaluating its SPC-15 nasal spray in healthy subjects: an Open-Label, Single Ascending Dose (SAD) study and an Open-Label, Multiple Ascending Dose (MAD) study.

NewsAllucent is developing enhancements to the Thread technological platform.Allucent will also work with Thread to implement a variety of enhancements to the Thread technological platform and suite of configurable integrations to support industry-leading participant and research site experiences for programs focused on preparing for public health emergencies and pandemics.